Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) Operating Income (2016 - 2025)

Historic Operating Income for Pharma (IGC) over the last 17 years, with Q3 2025 value amounting to -$2.9 million.

  • Pharma's Operating Income fell 6471.59% to -$2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.1 million, marking a year-over-year increase of 1319.18%. This contributed to the annual value of -$7.4 million for FY2025, which is 2400.49% up from last year.
  • According to the latest figures from Q3 2025, Pharma's Operating Income is -$2.9 million, which was down 6471.59% from -$1.9 million recorded in Q2 2025.
  • In the past 5 years, Pharma's Operating Income registered a high of -$1.4 million during Q1 2025, and its lowest value of -$6.5 million during Q1 2022.
  • Its 5-year average for Operating Income is -$2.7 million, with a median of -$2.4 million in 2024.
  • Per our database at Business Quant, Pharma's Operating Income crashed by 15942.72% in 2021 and then surged by 4627.38% in 2024.
  • Quarter analysis of 5 years shows Pharma's Operating Income stood at -$2.4 million in 2021, then increased by 4.49% to -$2.3 million in 2022, then crashed by 31.61% to -$3.0 million in 2023, then soared by 37.36% to -$1.9 million in 2024, then tumbled by 54.37% to -$2.9 million in 2025.
  • Its Operating Income was -$2.9 million in Q3 2025, compared to -$1.9 million in Q2 2025 and -$1.4 million in Q1 2025.